Molecular Diagnostic


Trent Lastinger & Associates is passionate and committed to partnering with companies that are on a mission to aggressively create cutting edge technologies that can more accurately and efficiently identify those difficult to diagnose diseases.

Trent Lastinger is the President and driving force serving Molecular Diagnostics and Molecular Medicine.  His impeccable track record, with a focus approach on accountable results has led to a history of exceeding his clients’ expectations. His success was directly related to his outstanding ability to identify and retain top talent within these markets. As a result, his practice is one of the most recognized within Molecular Diagnostics and Molecular Medicine  “Extraordinary people deliver extraordinary results.”

Our firm focuses on companies involved with technologies that constitute molecular diagnostics-like first-generation amplification, DNA probes, fluorescent in situ hybridization (FISH), second-generation biochips and micro fluidics, next-generation signal detection, biosensors, and molecular labels-which are influencing the discovery of therapeutic molecules, the predictive screening, diagnosis of patients, monitoring, theranostics and the optimization of drug therapy through pharmacogenomics.  Lastinger & Associates clients’ customers are focused on selling to the hospitals, clinics, reference laboratories and doctors’ offices.

  • Nucleic Acid Test Applications
  • Blood Testing and Infectious Diseases
  • Diagnostic Testing Using DNA
  • Cancer Detection Using PCR
  • Microbiology Testing
  • Blood Screening
  • SNPs in Clinical Diagnostics
  • Forensics Market
  • Bioterrorism and Molecular Diagnostics
  • Cystic Fibrosis Testing
  • HLA Sequencing-Based Typing Kits
  • Cytogenetic Testing
  • Developments in Biochips for Clinical Applications
  • Medical Genetics
  • Oncology